Detection of immune complex-like materials in cancer patients' sera

a comparative study of results obtained with the C1q deviation and C1q binding tests

R. D. Rossen, R. H. Zubler, N. K. Day, M. A. Reisberg, A. C. Morgan, J. U. Gutterman, Evan M Hersh

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

In a collaborative study involving three laboratories, randomly coded sera from 47 patients and healthy donors were tested for soluble immune complexes by two versions of the C1q BT and by the C1q DT. Analysis of ranked data showed a close correlation between results obtained in all laboratories as well as good reproducibility on testing coded duplicate samples included in each panel of sera. However, with the use of values for normal donors established independently in each laboratory, the tests did not always agree in discriminating normal from abnormal sera, particularly with sera from cancer patients. Results reflected to some extent the methods used to inactivate the endogenous C1 complex in the test sera. Studies of 130 additional cancer patients revealed that 44 (34%) gave abnormal C1q BT values when inactivated with EDTA but only 35 (27%) were abnormal when heat inactivated (56° for 30 min). Similarly 12 of 65 sera (18%) from patients with nonneoplastic diseases and 10 of 80 (13%) from healthy donors gave significantly abnormal results after addition of EDTA. Eight (12%) of the disease and 6 (8%) of the healthy controls' sera were similarly outside normal limits when heat inactivated. Repeated freezing and thawing of sera or changes in the concentration of PEG used to precipitate complex-bound 125I-C1q influenced C1q BT results more than duration of storage at -70°C or changes ascribed to presence or absence of rheumatoid factors and CRP.

Original languageEnglish (US)
Pages (from-to)191-204
Number of pages14
JournalThe Journal of Laboratory and Clinical Medicine
Volume91
Issue number2
StatePublished - 1978
Externally publishedYes

Fingerprint

Antigen-Antibody Complex
Edetic Acid
Serum
Neoplasms
Thawing
Rheumatoid Factor
Freezing
Polyethylene glycols
Precipitates
Tissue Donors
Hot Temperature
Testing
Reference Values

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Detection of immune complex-like materials in cancer patients' sera : a comparative study of results obtained with the C1q deviation and C1q binding tests. / Rossen, R. D.; Zubler, R. H.; Day, N. K.; Reisberg, M. A.; Morgan, A. C.; Gutterman, J. U.; Hersh, Evan M.

In: The Journal of Laboratory and Clinical Medicine, Vol. 91, No. 2, 1978, p. 191-204.

Research output: Contribution to journalArticle

@article{7bbe18adefb64cbe8eb5b2eef1055858,
title = "Detection of immune complex-like materials in cancer patients' sera: a comparative study of results obtained with the C1q deviation and C1q binding tests",
abstract = "In a collaborative study involving three laboratories, randomly coded sera from 47 patients and healthy donors were tested for soluble immune complexes by two versions of the C1q BT and by the C1q DT. Analysis of ranked data showed a close correlation between results obtained in all laboratories as well as good reproducibility on testing coded duplicate samples included in each panel of sera. However, with the use of values for normal donors established independently in each laboratory, the tests did not always agree in discriminating normal from abnormal sera, particularly with sera from cancer patients. Results reflected to some extent the methods used to inactivate the endogenous C1 complex in the test sera. Studies of 130 additional cancer patients revealed that 44 (34{\%}) gave abnormal C1q BT values when inactivated with EDTA but only 35 (27{\%}) were abnormal when heat inactivated (56° for 30 min). Similarly 12 of 65 sera (18{\%}) from patients with nonneoplastic diseases and 10 of 80 (13{\%}) from healthy donors gave significantly abnormal results after addition of EDTA. Eight (12{\%}) of the disease and 6 (8{\%}) of the healthy controls' sera were similarly outside normal limits when heat inactivated. Repeated freezing and thawing of sera or changes in the concentration of PEG used to precipitate complex-bound 125I-C1q influenced C1q BT results more than duration of storage at -70°C or changes ascribed to presence or absence of rheumatoid factors and CRP.",
author = "Rossen, {R. D.} and Zubler, {R. H.} and Day, {N. K.} and Reisberg, {M. A.} and Morgan, {A. C.} and Gutterman, {J. U.} and Hersh, {Evan M}",
year = "1978",
language = "English (US)",
volume = "91",
pages = "191--204",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Detection of immune complex-like materials in cancer patients' sera

T2 - a comparative study of results obtained with the C1q deviation and C1q binding tests

AU - Rossen, R. D.

AU - Zubler, R. H.

AU - Day, N. K.

AU - Reisberg, M. A.

AU - Morgan, A. C.

AU - Gutterman, J. U.

AU - Hersh, Evan M

PY - 1978

Y1 - 1978

N2 - In a collaborative study involving three laboratories, randomly coded sera from 47 patients and healthy donors were tested for soluble immune complexes by two versions of the C1q BT and by the C1q DT. Analysis of ranked data showed a close correlation between results obtained in all laboratories as well as good reproducibility on testing coded duplicate samples included in each panel of sera. However, with the use of values for normal donors established independently in each laboratory, the tests did not always agree in discriminating normal from abnormal sera, particularly with sera from cancer patients. Results reflected to some extent the methods used to inactivate the endogenous C1 complex in the test sera. Studies of 130 additional cancer patients revealed that 44 (34%) gave abnormal C1q BT values when inactivated with EDTA but only 35 (27%) were abnormal when heat inactivated (56° for 30 min). Similarly 12 of 65 sera (18%) from patients with nonneoplastic diseases and 10 of 80 (13%) from healthy donors gave significantly abnormal results after addition of EDTA. Eight (12%) of the disease and 6 (8%) of the healthy controls' sera were similarly outside normal limits when heat inactivated. Repeated freezing and thawing of sera or changes in the concentration of PEG used to precipitate complex-bound 125I-C1q influenced C1q BT results more than duration of storage at -70°C or changes ascribed to presence or absence of rheumatoid factors and CRP.

AB - In a collaborative study involving three laboratories, randomly coded sera from 47 patients and healthy donors were tested for soluble immune complexes by two versions of the C1q BT and by the C1q DT. Analysis of ranked data showed a close correlation between results obtained in all laboratories as well as good reproducibility on testing coded duplicate samples included in each panel of sera. However, with the use of values for normal donors established independently in each laboratory, the tests did not always agree in discriminating normal from abnormal sera, particularly with sera from cancer patients. Results reflected to some extent the methods used to inactivate the endogenous C1 complex in the test sera. Studies of 130 additional cancer patients revealed that 44 (34%) gave abnormal C1q BT values when inactivated with EDTA but only 35 (27%) were abnormal when heat inactivated (56° for 30 min). Similarly 12 of 65 sera (18%) from patients with nonneoplastic diseases and 10 of 80 (13%) from healthy donors gave significantly abnormal results after addition of EDTA. Eight (12%) of the disease and 6 (8%) of the healthy controls' sera were similarly outside normal limits when heat inactivated. Repeated freezing and thawing of sera or changes in the concentration of PEG used to precipitate complex-bound 125I-C1q influenced C1q BT results more than duration of storage at -70°C or changes ascribed to presence or absence of rheumatoid factors and CRP.

UR - http://www.scopus.com/inward/record.url?scp=0017891244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017891244&partnerID=8YFLogxK

M3 - Article

VL - 91

SP - 191

EP - 204

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 2

ER -